Literature DB >> 20506007

Effect of extended-release niacin or ezetimibe on carotid intimal thickness: the ARBITER-HALTS Study.

John A Farmer1.   

Abstract

Entities:  

Year:  2010        PMID： 20506007     DOI： 10.1007/s11883-010-0087-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  5 in total

Review 1.  Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.

Authors:  Antonio M Gotto; John A Farmer
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-12

2.  The HALTS trial--halting atherosclerosis or halted too early?

Authors:  Roger S Blumenthal; Erin D Michos
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245

3.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

4.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Authors:  P L Canner; K G Berge; N K Wenger; J Stamler; L Friedman; R J Prineas; W Friedewald
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

Review 5.  Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

Authors:  John R Guyton
Journal:  Curr Opin Lipidol       Date:  2007-08       Impact factor: 4.776
  5 in total
  1 in total

Review 1.  Niacin for primary and secondary prevention of cardiovascular events.

Authors:  Stefan Schandelmaier; Matthias Briel; Ramon Saccilotto; Kelechi K Olu; Armon Arpagaus; Lars G Hemkens; Alain J Nordmann
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.